. 2015 Mar 20;10(3):e0120230. doi: 10.1371/journal.pone.0120230

Table 1. Characteristics of the patients.

Median, IQR	All	Good outcome	Poor Outcome	Recanalized	Non-recanalized
	N = 99	N = 54	N = 43	N = 77	N = 20
Clinical data
Age (years)	70 56–82	63.9^*	78	73.2	70.8
Age (years)	56–82	54–78	57–85	56–83	52–81
Gender (n,%) male	57	35/54	21/43	48/77	9/20
Gender (n,%) male	57%	64%	49%	62%	45%
Initial NIHSS	13	11^*	19	13	15
Initial NIHSS	8–19	7–14	12–22	8–19	11–19
Day 1 NIHSS	9	4^*	16	9^**	15
Day 1 NIHSS	3–17	2–8	11–19	3–15	7–19
3-month mRS 0–2 (n, %)	54/97	54	0	31/75	12/20
3-month mRS 0–2 (n, %)	56%	100%	0%	41%	60%
Glycaemic data
Initial CGT (mmol/l)	6.7	6.2^*	7.4	6.8	6.7
Initial CGT (mmol/l)	5.8–8.1	5.4–7.1	6.4–8.4	5.8–8.1	6–8
Mean 24-h CGT (mmol/l)	5.8	5.6^*	6.1	5.8	5.9
Mean 24-h CGT (mmol/l)	5.3–6.6	5.1–6.3	5.5–7	5.2–6.6	5.3–6.6
Insulin regimen (SIT) n,%	46	26/54	18/43	35/77	9/20
Insulin regimen (SIT) n,%	46%	48%	42%	45%	45%
MRI data
Time to FU MRI (hours)	29.7	30	30.2	30.8	27
Time to FU MRI (hours)	26.3–36.1	26.4–35.7	26.5–39.8	27.7–36.5	25.3–31.2
Recanalization (n, %)	77/9	44/52	31/43	77	0
Recanalization (n, %)	79%	85%	71%	100%	0%
Initial Volume (cm³)	8.8	4.8^*	12.6	8.5	11.4
Initial Volume (cm³)	2.6–19	0.9–17.1	6.8–32.3	2.2–24.4	3.5–33.3
Follow-up volume (cm³)	23.9	14.3^*	54.9	22.5^**	63.1
Follow-up volume (cm³)	5.8–72	2–31.2	18.9–144.6	4.8–55.8	6.2–155
ADC_{abs (x 10} ^–6 _mm ² _/s)	730	776^*	656	756^**	585
ADC_{abs (x 10} ^–6 _mm ² _/s)	598–807	678–824	488–782	658–819	414–713
ADC_{cl (x 10} ^–6 _mm ² _/s)	796	791	802	805	786
ADC_{cl (x 10} ^–6 _mm ² _/s)	763–858	752–856	779–859	770–862	734–813
ADC_ratio	0.90	0.94^*	0.79	0.92^**	0.74
ADC_ratio	0.78–0.97	0.89–1	0.64–0.91	0.81–0.97	0.50–0.87

* p< 0.05 for the comparison between poor and good clinical outcome;

** p<0.05 for the comparison between recanalized and non-recanalized patients: mRS: modified Rankin scale: CGT: Capillary Glucose Test, SIT: Subcutaneous insulin therapy: FU: Follow-up.